Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}
• Allele Name: targeted mutation 3, Mario R Capecchi
• Allele ID: MGI:3710098
• Summary: 7 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc/Gt(ROSA)26Sor^+	involves: 129S1/Sv * 129X1/SvJ	MGI:3843452
cn2	Gt(ROSA)26Sor^tm1(cre/ERT)Nat/Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc	involves: 129 * 129S1/Sv * 129X1/SvJ	MGI:3843451
cn3	Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc/Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc Pax3^tm1(cre)Joe/Pax3^tm1(cre)Joe	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3711000
cn4	Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc/Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc Hprt1^tm1(CAG-cre)Mnn/Hprt1^tm1(CAG-cre)Mnn	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3711002
cn5	Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc/Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc Myf5^tm1(cre)Mrc/Myf5^tm1(cre)Mrc	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3711004
cn6	Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc/Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc Myf6^tm1(cre)Mrc/Myf6^tm1(cre)Mrc	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3710997
cn7	Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc/Gt(ROSA)26Sor^tm3(SS18/EGFP)Mrc Pax7^tm1(cre)Mrc/Pax7^tm1(cre)Mrc	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3710999

Genotype
MGI:3843452

ht1

• Allelic Composition: Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal cell death ( J:147728 )

• mouse embryonic fibroblasts exposed to TAT-cre exhibit cell death unlike cells not exposed to TAT-cre

Genotype
MGI:3843451

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}
• Genetic Background: involves: 129 * 129S1/Sv * 129X1/SvJ

mortality/aging

premature death ( J:147728 )

• mice treated with tamoxifen exhibit a dosage and frequency dependent lethality dieing by 16 months unlike in mice lacking cre expression

neoplasm

increased tumor incidence ( J:147728 )

• all mice develop tumors in the juxta-articular region in the limbs with some evidence of calcification

• following tamoxifen treatment, all mice develop tumors in the juxta-articular region in the limbs with some evidence of calcification

increased sarcoma incidence ( J:147728 )

• mice develop synovial sarcomas

• following tamoxifen treatment, mice develop synovial sarcomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
synovial sarcoma		DOID:5485	OMIM:300813	J:147728

Genotype
MGI:3711000

cn3

• Allelic Composition: Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}/Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}; Pax3^tm1(cre)Joe/Pax3^tm1(cre)Joe
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:120967 )

• no embryos are recovered at E13.5 but are present at E10.5

Genotype
MGI:3711002

cn4

• Allelic Composition: Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}/Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}; Hprt1^{tm1(CAG-cre)Mnn}/Hprt1^{tm1(CAG-cre)Mnn}
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

prenatal lethality, complete penetrance ( J:120967 )

♀ • no pups were recovered

embryo

abnormal embryonic tissue morphology ( J:120967 )

♀ • at E8.5, embryonic tissue is highly disorganized

Genotype
MGI:3711004

cn5

• Allelic Composition: Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}/Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}; Myf5^tm1(cre)Mrc/Myf5^tm1(cre)Mrc
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

postnatal lethality, incomplete penetrance ( J:120967 )

• about 8% of mice die by 2 months of age

neoplasm

increased tumor incidence ( J:120967 )

• at 3 to 5 months, 18 of 18 surviving mice developed multiple tumors (3 to 5 per mouse) compared to over 100 control mice who did not develop tumors at more than 1 year of age

• however, mice that died prior to 2 months of age did not have tumors and did not die from tumor-related causes

• small and potentially metastatic tumors are detected

• most tumors are located within the skeletal muscle in the limbs and intercostals regions with some non-skeletal muscle tissues (such as the cerebellum) harboring tumors

• tumors are vascularized, hemorrhagic and cystic spaces are detected in large tumors

increased sarcoma incidence ( J:120967 )

• synovial sarcomas are detected with monophasic (13) outnumbering biphasic (3)

• myxoid and fibrous changes are observed

muscle

abnormal muscle development ( J:120967 )

• myf5+ lineage cells undergo increased apoptosis ate E11.5 and by E15.5 are absent

• however, myf5+ cells near future rib cartilage and skeletal musculogenesis are normal

growth/size/body

decreased body size ( J:120967 )

• about 8% of mice are born small

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
synovial sarcoma		DOID:5485	OMIM:300813	J:120967

Genotype
MGI:3710997

cn6

• Allelic Composition: Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}/Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}; Myf6^tm1(cre)Mrc/Myf6^tm1(cre)Mrc
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

postnatal lethality, complete penetrance ( J:120967 )

• mice die by 6 months of age

neoplasm

neoplasm ( J:120967 )

N • unlike in other Gt(ROSA)26Sor^tm3(SS18)Mrc homozygously activated mice, no tumors form

muscle

myopathy ( J:120967 )

• myopathy is characterized by abnormal wavy fiber and limited rhabdomyolysis

Genotype
MGI:3710999

cn7

• Allelic Composition: Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}/Gt(ROSA)26Sor^{tm3(SS18/EGFP)Mrc}; Pax7^tm1(cre)Mrc/Pax7^tm1(cre)Mrc
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

lethality throughout fetal growth and development, complete penetrance ( J:120967 )

• no pups are born but they can be recovered at E15.5

muscle

abnormal muscle development ( J:120967 )

• Pax7+ lineage cells are mostly absent except in the proximity to cartilaginous regions of the developing maxilla and nasal turbinates